Benitec Biopharma Inc.
BNTC
$11.50
-$0.18-1.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.25% | -52.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.46% | -42.93% | |||
| Operating Income | -36.46% | 42.93% | |||
| Income Before Tax | -32.04% | 44.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.04% | 44.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.04% | 44.48% | |||
| EBIT | -36.46% | 42.93% | |||
| EBITDA | -36.50% | 42.96% | |||
| EPS Basic | -19.27% | 44.97% | |||
| Normalized Basic EPS | -19.27% | 44.98% | |||
| EPS Diluted | -19.27% | 44.97% | |||
| Normalized Diluted EPS | -19.27% | 44.98% | |||
| Average Basic Shares Outstanding | 10.72% | 0.88% | |||
| Average Diluted Shares Outstanding | 10.72% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||